Department of Otorhinolaryngology, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey.
Department of Otorhinolaryngology, Istanbul Education and Research Hospital, Istanbul, Turkey.
Clin Otolaryngol. 2023 Jul;48(4):623-629. doi: 10.1111/coa.14056. Epub 2023 Mar 27.
The present study aimed to investigate the in vivo activity of nasal irrigation (NI) with saline, NI with povidone-iodine (PVP-I) 1%, NI with a mix of hypertonic alkaline and PVP-I 1% against Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2).
This study was a prospective randomised clinical trial.
A multicenter study involving tertiary care centres.
The study included adult outpatients whose qualitative SARS-CoV-2 RT-PCR tests in nasopharyngeal swabs were positive. One hundred twenty patients were divided into four equal groups. Standard COVID-19 treatment was given to Group 1, NI containing saline was added to patients' treatment in Group 2, NI containing 1% PVP-I solution was added to patients' treatment in Group 3, and NI containing 1% PVP-I solution and the hypertonic alkaline solution was added to patients' treatment in Group 4.
On the first day of diagnosis (Day 0), nasopharyngeal swab samples were taken, on the third and fifth days the nasopharyngeal viral load (NVL) reduction in quantitative RT-PCR test was calculated.
Between the zeroth to third days and zeroth to fifth days, the NVL reduction was significant in all groups (p < .05). In paired comparisons of groups, the NVL decrease in Group 4 in the first 3 days was significantly lower than all groups (p < .05). The NVL decrease in Groups 3 and 4 in the first 5 days were significantly lower than Group 1 (p < .05).
This study revealed that the use of NI of 1% PVP-I and the hypertonic alkaline solution mixture was more effective in reducing NVL.
本研究旨在探讨鼻腔冲洗(NI)生理盐水、聚维酮碘(PVP-I)1%、高渗碱性和 PVP-I 1%混合物对严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)的体内活性。
这是一项前瞻性随机临床试验。
多中心研究涉及三级护理中心。
该研究包括定性 SARS-CoV-2 RT-PCR 检测鼻咽拭子阳性的成年门诊患者。120 名患者被分为四组。第 1 组给予标准 COVID-19 治疗,第 2 组在患者治疗中加入含生理盐水的 NI,第 3 组在患者治疗中加入 1%PVP-I 溶液,第 4 组在患者治疗中加入 1%PVP-I 溶液和高渗碱性溶液。
在诊断的第 1 天(第 0 天),采集鼻咽拭子样本,第 3 天和第 5 天,计算定量 RT-PCR 检测中鼻咽病毒载量(NVL)的减少。
在第 0 天至第 3 天和第 0 天至第 5 天之间,所有组的 NVL 减少均有统计学意义(p<0.05)。在组间配对比较中,第 4 组在第 3 天的 NVL 下降明显低于所有组(p<0.05)。第 3 组和第 4 组在第 5 天的 NVL 下降明显低于第 1 组(p<0.05)。
本研究表明,使用 1%PVP-I 和高渗碱性溶液混合物的 NI 更有效地降低 NVL。